Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Claudin18.2 CAR-T in Advanced Pancreatic and Gastric Cancer
NCT05620732Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of Claudin18.2 CAR-T cells in pancreatic cancer (PC) and gastric cancer (GC), sponsored by Shenzhen University General Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 30 days. Started Oct 2022; status: recruiting.
02
Drugs
Claudin18.2 CAR-T cells
03
Conditions
pancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT05620732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620732.